China plans to accelerate the establishment of a tiered healthcare delivery system, focusing on strengthening primary-level medical capacity to manage common and chronic diseases such as hypertension and diabetes, authorities said.

At present, domestic blood typing instruments have covered microplate, MGT, tube method, and other international mainstream test methods, and they can provide highly automatic and standardized blood typing process, which play an important role in clinical transfusion. Current status of domestic blood typing instruments is mainly characterized by normative, standard and convenient operation; high sensitivity and excellent accuracy; high test efficiency; open reagent; intuitive, stable, reliable, clear and easy to save results; and data management by PC.

Illumina and Genetic Alliance said on Tuesday that they are launching a new program to expand patient access to whole-genome sequencing around the world.

Roche has again been recognized as one of the most sustainable companies in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance.

On November 15, 2021, Vazyme Biotech Co., Ltd. (hereinafter referred to as "Vazyme") was listed on SSE STAR Market. Stock abbreviation: Vazyme, stock code: 688105. The issue price is 55 yuan/share, and the opening price is 74 yuan/share.

The US Food and Drug Administration on Monday released revised guidance on its regulatory priorities and policies for COVID-19 tests.

Siemens Healthineers (ETR:SHL) shares ticked up today on fourth-quarter results that topped the consensus sales forecast.

An artificial intelligence (AI)-based technology rapidly diagnoses rare disorders in critically ill children with high accuracy, according to a report by researchers from University of Utah (U Of U) Health, Fabric Genomics, and collaborators on a study led by Rady Children’s Hospital in San Diego.

DiaSorin said in Q3 it saw a strong recovery of non-COVID test sales including for latent tuberculosis and other infectious diseases as well as gastrointestinal infections.

On November 10, Wuhan Landing Med officially announced that it had completed the round-D financing of RMB 320 million, which was led by Ali Health and followed by Ether Capital.

The funding will be used to provide purchase commitments to manufacturers so they can scale up test production.

Meridian Bioscience announced on Wednesday that its Revogene SARS-CoV-2 test has received Emergency Use Authorization from the US Food and Drug Administration.